Login to Your Account

Deals And M&A NEWS

Xencor Inc.'s broadly enabling platform made possible "the calculated trade-off" by Novartis AG that let his bispecific antibody firm hang onto U.S. rights for its pair of lead compounds in a deal that could be worth as much as $2.4 billion-plus.

SHANGHAI – Innovent Biologics Inc., an antibody-focused company based in Suzhou, is betting that the best things will come in pairs.

Mesoblast Ltd. lost more than a third of its market value Tuesday as Teva Pharmaceutical Industries Ltd. returned full development and commercialization rights to its advanced chronic heart failure therapy, MPC-150-IM.

More Deals And M&A Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: